Kosmos Trio and Ejection Fraction Pivotal Study

Sponsor
EchoNous Inc. (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT06027164
Collaborator
University of California, San Francisco (Other), Revival Research Institute LLC (Other), Centaur Labs (Other)
153
1
2.9
52.9

Study Details

Study Description

Brief Summary

This is a single-group, observational study which will involve obtaining two echo scans of recruited patients. All recruited patients will undergo echo scans by both novice users (nurses) and experts (echo sonographers). Image quality between novices and experts as well as the ability to calculate LVEF from novice and expert scans and the quality of the LVEF calculated via KOSMOS-EF compared to LVEF calculations by expert cardiologists will occur in post-hoc Echo image analysis

Condition or Disease Intervention/Treatment Phase
  • Device: Portable Ultrasound System

Study Design

Study Type:
Observational
Actual Enrollment :
153 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Kosmos Trio and Ejection Fraction Pivotal Study
Actual Study Start Date :
Aug 4, 2023
Anticipated Primary Completion Date :
Sep 30, 2023
Anticipated Study Completion Date :
Oct 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Study Subjects

Ultrasound scans conducted by novice users and experts on this cohort.

Device: Portable Ultrasound System
EchoNous KOSMOS

Outcome Measures

Primary Outcome Measures

  1. Assessment of Global Left Ventricular Function [Up to 2 months from the completion of the study or when all expert cardiologists readers independently complete their assessments]

    A panel of cardiologists will access and determine via a majority vote if a study exam acquired by a nurses is of sufficient image quality to make a qualitative visual assessment of the Global Left Ventricular Function.

  2. Assessment of Left Ventricular Size [Up to 2 months from the completion of the study or when all expert cardiologists readers independently complete their assessments]

    A panel of cardiologists will access and determine via a majority vote if a study exam acquired by a nurse is of sufficient image quality to make a qualitative visual assessment of the Left Ventricular Size.

  3. Assessment of Non-Trivial Pericardial Effusion [Up to 2 months from the completion of the study or when all expert cardiologists readers independently complete their assessments]

    A panel of cardiologists will access and determine via a majority vote if a study exam acquired by a nurse is of sufficient image quality to make a qualitative visual assessment of Non-Trivial Pericardial Effusion.

  4. Assessment of Right Ventricular Size [Up to 2 months from the completion of the study or when all expert cardiologists readers independently complete their assessments]

    A panel of cardiologists will access and determine via a majority vote if a study exam acquired by a nurse is of sufficient image quality to make a qualitative visual assessment of Right Ventricle Size.

Secondary Outcome Measures

  1. Assessment of Automatic Structure Labelling [Up to 2 months from the completion of the study or when all expert cardiologists readers independently complete their assessments]

    A panel of cardiologists will access and determine via a majority vote if the frame-level false discovery rate (FDR) of automated cardiac structure labeling as determined by expert cardiologists for scans acquired by cardiac sonographers.

  2. Manual vs. KOSMOS-EF for Sonographer Scans [Up to 2 months from the completion of the study or when all expert cardiologists readers independently complete their assessments]

    Measurements are computed for A4C and A2C scans acquired by sonographers . We will compare KOSMOS-EF LVEF calculation to LVEF calculated by a panel of cardiologists via a majority vote.

  3. Assessment of Left Atrial Size [Up to 2 months from the completion of the study or when all expert cardiologists readers independently complete their assessments]

    A panel of cardiologists will access and determine via a majority vote if a study exam acquired by a nurse is of sufficient image quality to make a qualitative visual assessment of Left Atrial Size.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 89 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Aged 18-89 years of age

  • Have capacity to provide written consent either themselves or via healthcare proxy as determined by subjects' clinical care teams

  • Have an anticipated timeline in the EDOU long enough to allow for completion of study procedures without causing delay to subjects' usual clinical care

Exclusion Criteria:
  • Heart rate > 110 beats per minute at the time of recruitment

  • Pregnant women

  • Prior chest surgery

  • Chest wall deformities or injuries (i.e. wounds, infections, etc)

  • Limited mobility precluding them from turning in bed independently

  • Speak a primary language other than English or Spanish

  • Vulnerable populations including: patients being evaluated for psychiatric crises, incarcerated individuals

  • Unwilling or unable to consent to study procedures

Contacts and Locations

Locations

Site City State Country Postal Code
1 Revival Research Institute LLC Dearborn Michigan United States 48126

Sponsors and Collaborators

  • EchoNous Inc.
  • University of California, San Francisco
  • Revival Research Institute LLC
  • Centaur Labs

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
EchoNous Inc.
ClinicalTrials.gov Identifier:
NCT06027164
Other Study ID Numbers:
  • ECHO-004
First Posted:
Sep 7, 2023
Last Update Posted:
Sep 7, 2023
Last Verified:
Sep 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 7, 2023